Pharmacological interventions for fertility preservation during chemotherapy: A systematic review and meta-analysis

Breast Cancer Research and Treatment

Volumn 122, Issue 3, 2010, Pages 803-811

  Ben Aharon, Irit ^a,b   Gafter Gvili, Anat ^a,b   Leibovici, Leonard ^b,c   Stemmer, Salomon M ^a,b  

^a Davidoff Center   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

Author keywords

GnRH agonists; Oral contraceptives; Ovarian failure

Indexed keywords

BUSERELIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GONADORELIN AGONIST; GOSERELIN; IFOSFAMIDE; LEUPRORELIN; METHOTREXATE; ORAL CONTRACEPTIVE AGENT; TRIPTORELIN; ANTINEOPLASTIC AGENT; FERTILITY PROMOTING AGENT;

AMENORRHEA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE FERTILITY; FOLLITROPIN BLOOD LEVEL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; OLIGOMENORRHEA; ORGAN PRESERVATION; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; OVARIAN RESERVE; OVARY INSUFFICIENCY; PREGNANCY RATE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; CHEMICALLY INDUCED; FEMALE; INFERTILITY; NEOPLASMS; PATHOLOGY; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FERTILITY AGENTS, FEMALE; HUMANS; INFERTILITY; NEOPLASMS; OVARIAN FAILURE, PREMATURE; PREGNANCY; TREATMENT OUTCOME; PRIMARY OVARIAN INSUFFICIENCY;

EID: 77955557956     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0996-7     Document Type: Article

References (58)

1. MT Knobf 2006 The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors Oncologist 11 96 110 10.1634/theoncologist.11-2-96 16476831 (Pubitemid 43261757)
2. A Elis A Tevet R Yerushalmi, et al. 2006 Fertility status among women treated for aggressive non-Hodgkin's lymphoma Leuk Lymphoma 47 623 627 10.1080/10428190500353877 16690520
3. B Thewes B Meiser A Taylor, et al. 2005 Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer J Clin Oncol 23 5155 5165 10.1200/JCO.2005.07.773 1:STN:280:DC%2BD2MzptlSrsw%3D%3D 16051957 (Pubitemid 46224024)
4. M Sonmezer H Bang K Oktay 2008 GnRH analogues preserve gonadal function without preserving fertility? Oncologist 13 615 617 10.1634/theoncologist.2008- 0053 (Pubitemid 351872881)
5. SJ Lee LR Schover AH Partridge P Patrizio WH Wallace K Hagerty LN Beck LV Brennan K Oktay American Society of Clinical Oncology 2006 American Society of Clinical Oncology recommendations on fertility preservation in cancer patients J Clin Oncol 24 2917 2931 10.1200/JCO.2006.06.5888 16651642 (Pubitemid 46655598)
6. JH Waxman R Ahmed D Smith, et al. 1987 Failure to preserve fertility in patients with Hodgkin's disease Cancer Chemother Pharmacol 19 159 162 10.1007/BF00254570 1:STN:280:DyaL2s7ovVSlug%3D%3D 3105906
7. Z Blumenfeld I Avivi S Linn, et al. 1998 Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotropin-releasing hormone agonist in parallel to chemotherapy Hum Reprod 11 1620 1626
8. Z Blumenfeld D Shapiro M Shteinberg, et al. 2000 Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy Lupus 9 401 405 10.1191/096120300678828596 1:CAS:528:DC%2BD3cXlvF2jtL4%3D 10981642
9. B Pereyra Pacheco JM Mendez Ribas G Milone, et al. 2001 Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report Gynecol Oncol 81 391 397 10.1006/gyno.2001.6181 1:STN:280:DC%2BD3M3nslOmtg%3D%3D 11371127 (Pubitemid 32494652)
10. M Petri R Brodsky R Jones, et al. 2004 High dose cyclophosphamide can cause ovarian failure Arthritis Rheum 50 Suppl 9 408
11. Z Blumenfeld A Eckman 2005 Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a J Natl Cancer Inst Monogr 34 40 43 10.1093/jncimonographs/lgi015 1:CAS:528:DC%2BD2MXjt1Clsrg%3D 15784821
12. EJ Dann R Epelbaum I Avivi, et al. 2005 Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma Hum Reprod 20 2247 2249 10.1093/humrep/dei018 1:CAS:528:DC%2BD2MXmt1Gnurg%3D 15817583 (Pubitemid 41418514)
13. EC Somers W Marder GM Christman, et al. 2005 Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus Arthritis Rheum 52 2761 2767 10.1002/art.21263 1:CAS:528:DC%2BD2MXhtFeltrnN 16142702 (Pubitemid 41369104)
14. C Castelo-Branco B Nomdedeu A Camus, et al. 2007 Use of gonadotropin releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy Fertil Steril 87 703 706 1:CAS:528:DC%2BD2sXksVylur4%3D
15. L Giuseppe G Attilio DN Edoardo, et al. 2007 Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD) Hematology 12 141 147 10.1080/10245330600954072 17454195 (Pubitemid 46605523)
16. F Azem N Samara T Cohen, et al. 2008 Assessment of ovarian reserve following ovarian tissue banking and/or GnRH-a co-treatment prior to chemotherapy in patients with Hodgkin's disease J Assist Reprod Genet 25 535 538 10.1007/s10815-008-9276-4 19015974
17. Z Blumenfeld I Avivi A Eckman, et al. 2008 Gonadotropin-releasing hormone agonist decreases chemotherapy induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma Fertil Steril 89 166 173 10.1016/j.fertnstert.2007.02.010 1:CAS:528:DC%2BD1cXhslSrtr4%3D 17601603
18. A Cigni R Faedda MM Atzeni, et al. 2008 Hormonal strategies for fertility preservation in patients receiving cyclophosphamide to treat glomerulonephritis: a nonrandomized trial and review of the literature Am J Kidney Dis 52 887 896 10.1053/j.ajkd.2008.06.017 1:CAS:528:DC%2BD1cXhsVarsbzM 18971013
19. Ismail-Khan R, Minton S, Cox C et al (2008) Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: a randomized trial using the GnRH agonist (triptorelin) during chemotherapy. J Clin Oncol 26:(abstr 524)
20. M Huser I Crha P Ventruba, et al. 2008 Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients Hum Reprod 23 863 868 10.1093/humrep/den005 1:CAS:528:DC%2BD1cXmslKktL8%3D 18258763
21. A Badawy A Elnashar M El-Ashry, et al. 2009 Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study Fertil Steril 91 694 697 10.1016/j.fertnstert.2007. 12.044 1:CAS:528:DC%2BD1MXnslWms7k%3D 18675959
22. Nitzschke M, Raddatz J,Bohlmann MK et al (2010) GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin's lymphoma patients. Arch Gynecol Obstet 282(1):83-88
23. A Sverrisdottir M Nystedt H Johansson, et al. 2009 Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial Breast Cancer Res Treat 117 561 567 10.1007/s10549-009-0313-5 1:CAS:528:DC%2BD1MXhtFegtbbK 19153828
24. E Whitehead SM Shalet G Blackledge, et al. 1983 The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease Cancer 52 988 993 10.1002/1097-0142(19830915)52:6<988::AID-CNCR2820520610>3.0. CO;2-6 1:STN:280:DyaL3s3osVOmtQ%3D%3D 6411321
25. A Longhi E Pignotti M Versari, et al. 2003 Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma Oncol Rep 10 151 155 12469162
26. K Behringer K Breuer T Reineke, et al. 2005 Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group J Clin Oncol 23 7555 7564 10.1200/JCO.2005.08.138 16234521 (Pubitemid 46291819)
27. Behringer K, Wildt L, Mueller H et al (2010) No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol (in press)
28. L Del Mastro T Catzeddu L Boni, et al. 2008 Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients Ann Oncol 17 74 78 10.1093/annonc/mdj029
29. HR Franke WM Smit I Vermes 2005 Gonadal protection by a gonadotropin-releasing hormone agonist depot in young women with Hodgkin's disease undergoing chemotherapy Gynecol Endocrinol 20 274 278 10.1080/09513590400027414 1:CAS:528:DC%2BD2MXkvFWqtbw%3D 16019373 (Pubitemid 40897393)
30. C Potolog-Nahari A Fishman I Cohen 2007 Protection of ovarian function and fertility using a combination of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist during cancer treatment in young females Gynecol Endocrinol 23 290 294 10.1080/09513590701327661 1:CAS:528:DC%2BD2sXmt1ansb4%3D 17558688 (Pubitemid 46897694)
31. F Recchia G Saggio G Amiconi, et al. 2006 Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma Cancer 106 514 523 10.1002/cncr.21646 1:CAS:528:DC%2BD28XhsFGiu74%3D 16388519 (Pubitemid 43157613)
32. C Teinturier O Hartmann D Valteau-Couanet, et al. 1998 Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure Bone Marrow Transplant 22 989 994 10.1038/sj.bmt.1701483 1:STN:280:DyaK1M%2FmsV2nug%3D%3D 9849696
33. PG Crosignani G Ragni GC Lombroso, et al. 1988 Ovarian stimulation of IVF patients: effects of the reversible hypogonadotropic state induced by GnRH agonist Hum Reprod 3 39 41 3147991
34. K Lutchman Singh S Muttukrishna, et al. 2007 Predictors of ovarian reserve in young women with breast cancer Br J Cancer 96 1808 1816 10.1038/sj.bjc.6603814 1:CAS:528:DC%2BD2sXmtlyqur8%3D 17533402 (Pubitemid 46912025)
35. RD van Beek MM van den Heuvel-Eibrink JS Laven, et al. 2007 Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood J Clin Endocrinol Metab 92 3869 3874 10.1210/jc.2006-2374 17726078 (Pubitemid 47607635)
36. A Bukman MJ Heineman 2001 Ovarian reserve testing and the use of prognostic models in patients with subfertility Hum Reprod Update 7 581 590 10.1093/humupd/7.6.581 1:STN:280:DC%2BD3MnotFKiuw%3D%3D 11727867 (Pubitemid 33069617)
37. JA Berlin D Rennie 1999 Measuring the quality of trials: the quality of quality scales JAMA 282 1083 1084 10.1001/jama.282.11.1083 1:STN:280: DyaK1MvitV2msA%3D%3D 10493209 (Pubitemid 29436458)
38. J Henderson R Gray P Brocklehurst 2007 Systematic review of effects of low-moderate prenatal alcohol exposure on pregnancy outcome BJOG 114 243 252 10.1111/j.1471-0528.2006.01163.x 1:STN:280:DC%2BD2s7hsFOjsA%3D%3D 17233797
39. JPT Higgins SG Thompson JJ Deeks, et al. 2003 Measuring inconsistency in meta-analyses BMJ 327 557 560 10.1136/bmj.327.7414.557 12958120
40. CA Sklar AC Mertens P Mitby, et al. 2008 Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study J Natl Cancer Inst 98 890 896
41. M Matsumoto M Miyauchi N Yamamoto, et al. 2000 Investigation of menstruation recovery after LH-RH agonist therapy for premenopausal patients with breast cancer Breast Cancer 7 237 240 10.1007/BF02967466 1:STN:280:DC%2BD3M3mvFKqsw%3D%3D 11029804
42. D Meirow 2000 Reproduction post-chemotherapy in young cancer patients Mol Cell Endocrinol 169 123 131 10.1016/S0303-7207(00)00365-8 1:CAS:528: DC%2BD3MXhsV2ntQ%3D%3D 11155944 (Pubitemid 32063311)
43. KM Ataya JA McKanna AM Weintraub, et al. 1985 Luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats Cancer Res 45 3651 3656 1:CAS:528: DyaL2MXltFKlsr0%3D 3926307
44. GS Letterie 2004 Anovulation in the prevention of cytotoxic-induced follicular attrition and ovarian failure Hum Reprod 19 831 837 10.1093/humrep/deh120 1:CAS:528:DC%2BD2cXitlyhtrk%3D 15033951 (Pubitemid 38456046)
45. A Imai T Furui 2007 Chemotherapy-induced female infertility and protective action of gonadotropin-releasing hormone analogues J Obstet Gynaecol 27 20 24 10.1080/01443610601056467 1:CAS:528:DC%2BD2sXjvVehtr4%3D 17365452
46. DR Danforth LK Arbogast CI Friedman 2005 Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists Fertil Steril 83 1333 1338 10.1016/j.fertnstert.2004.12.030 1:CAS:528: DC%2BD2MXltFSjtr8%3D 15866565 (Pubitemid 40615801)
47. RM Chapman SB Sutcliffe JS Malpas 1979 Cytotoxic induced ovarian failure in women with Hodgkin's disease. I. Hormonal function JAMA 242 1877 1881 10.1001/jama.242.17.1877 1:STN:280:DyaL3c%2FgvFKlsQ%3D%3D 480620 (Pubitemid 10219128)
48. ML Meistrich 1994 Failure to demonstrate hormonal protection of chemotherapy-induced fertility reduction in female rats Reprod Toxicol 8 277 278 10.1016/0890-6238(94)90013-2 1:STN:280:DyaK2czlsFOqsg%3D%3D 8075517
49. AJ Hsueh EA McGee M Hayashi, et al. 2000 Hormonal regulation of early follicle development in the rat ovary Mol Cell Endocrinol 163 95 100 10.1016/S0303-7207(99)00245-2 1:CAS:528:DC%2BD3cXlvV2ms7w%3D 10963880 (Pubitemid 30645591)
50. ML Meistrich G Shetty 2008 Hormonal suppression for fertility preservation in males and females Reproduction 136 691 701 10.1530/REP-08-0096 1:CAS:528:DC%2BD1MXns1Cktw%3D%3D 18515310
51. D Meirow G Assad J Dor, et al. 2004 The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice Hum Reprod 19 1294 1299 10.1093/humrep/deh257 1:CAS:528:DC%2BD2cXksVahu7o%3D 15117898 (Pubitemid 38807699)
52. RK Gupta JA Flaws 2005 Gonadotropin-releasing hormone (GnRH) analogues and the ovary: do GnRH antagonists destroy primordial follicles? Fertil Steril 83 1339 1342 10.1016/j.fertnstert.2005.01.089 1:CAS:528:DC%2BD2MXltFSjtr0%3D 15866566 (Pubitemid 40615802)
53. EY Adashi 1994 Long-term gonadotropin-releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms Hum Reprod 9 1380 1397 1:STN:280:DyaK2M%2FltFCgtQ%3D%3D 7962453
54. A Nagy AV Schally 2005 Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers Biol Reprod 73 851 859 10.1095/biolreprod.105.043489 1:CAS:528:DC%2BD2MXhtFGktLfE 16033997 (Pubitemid 41507486)
55. D Meirow J Rabinovici D Katz, et al. 2008 Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate Cancer 1 1634 1641
56. AM Quaas ES Ginsburg 2007 Prevention and treatment of uterine bleeding in hematologic malignancy Eur J Obstet Gynecol Reprod Biol 134 3 8 10.1016/j.ejogrb.2007.03.012 17467142 (Pubitemid 47332825)
57. E Porcu S Venturoli 2006 Progress with oocyte cryopreservation Curr Opin Obstet Gynecol 18 273 279 10.1097/01.gco.0000193015.96275.2d 16735826 (Pubitemid 43864726)
58. R Sharma A Hamilton J Beith 2008 LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women Cochrane Database Syst Rev 8 CD004562